List view / Grid view

News

Merck announces results from Phase 2b study of MK-8237, an investigational house dust mite sublingual allergen immunotherapy tablet

5 March 2014 | By

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting…

Roche Annual General Meeting 2014

4 March 2014 | By Roche

Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...

Raman images faster than ever before

4 March 2014 | By Renishaw

Renishaw’s new StreamLineHR™ Rapide option for its inVia Raman microscope enables the rapid collection of large amounts of Raman data...